TY - JOUR
T1 - Inactivation of Blood-Borne Enveloped Viruses with the Nonionic Detergent 2-[4-(2,4,4-Trimethylpentan-2-yl)Phenoxy]Ethanol Does Not Bias Clinical Chemistry Results
AU - Bailey, Adam L.
AU - Farnsworth, Christopher
N1 - Publisher Copyright:
© 2021 American Association for Clinical Chemistry. All rights reserved.
PY - 2021/9/1
Y1 - 2021/9/1
N2 - Background: Patients infected with virulent pathogens require the sophisticated diagnostic capabilities of a core laboratory for optimal care. This is especially true in outbreaks that strain healthcare system capacity. However, samples from such patients pose an infection risk for laboratory workers. We evaluated a strategy for mitigating this risk by preincubating specimens with 2-[4-(2,4,4-Trimethylpentan-2-yl)phenoxy]ethanol, a non-ionic detergent commonly calledTriton X-100. Methods: Lithium-heparinized plasma was mixed with the detergent Triton X-100 at 1%. Inactivation of Ebola virus (EBOV), yellow fever virus (YFV), and chikungunya virus (CHIKV) was assessed using a virus-outgrowth assay. The impact of 1% Triton X-100 dilution on the components of a complete metabolic panel (CMP) was assessed on a Roche Cobas analyzer with 15 specimens that spanned a large portion of the analytical measurement range. Results: Incubation with 1% Triton X-100 for 5 min was sufficient to completely inactivate EBOV and YFV spiked into plasma but did not completely inactivate CHIKV infectivity even after 60 min of incubation. This was true only for CHIKV when spiked into plasma; CHIKV was completely inactivated in cell culture medium. A bias of-0.78 mmol/L (95% CI,-2.41 to 0.85) was observed for CO2 and 5.79 U/L (95% CI,-0.05 to 11.63) was observed for aspartate aminotransferase after addition of Triton X-100. No other components of the CMP were affected by the addition of Triton X-100. Conclusions: Detergent-based inactivation of plasma specimens may be a viable approach to mitigating the risk that certain blood-borne pathogens pose to laboratory workers in an outbreak setting. However, the effectiveness of this method for inactivation may depend on the specimen type and pathogen in question.
AB - Background: Patients infected with virulent pathogens require the sophisticated diagnostic capabilities of a core laboratory for optimal care. This is especially true in outbreaks that strain healthcare system capacity. However, samples from such patients pose an infection risk for laboratory workers. We evaluated a strategy for mitigating this risk by preincubating specimens with 2-[4-(2,4,4-Trimethylpentan-2-yl)phenoxy]ethanol, a non-ionic detergent commonly calledTriton X-100. Methods: Lithium-heparinized plasma was mixed with the detergent Triton X-100 at 1%. Inactivation of Ebola virus (EBOV), yellow fever virus (YFV), and chikungunya virus (CHIKV) was assessed using a virus-outgrowth assay. The impact of 1% Triton X-100 dilution on the components of a complete metabolic panel (CMP) was assessed on a Roche Cobas analyzer with 15 specimens that spanned a large portion of the analytical measurement range. Results: Incubation with 1% Triton X-100 for 5 min was sufficient to completely inactivate EBOV and YFV spiked into plasma but did not completely inactivate CHIKV infectivity even after 60 min of incubation. This was true only for CHIKV when spiked into plasma; CHIKV was completely inactivated in cell culture medium. A bias of-0.78 mmol/L (95% CI,-2.41 to 0.85) was observed for CO2 and 5.79 U/L (95% CI,-0.05 to 11.63) was observed for aspartate aminotransferase after addition of Triton X-100. No other components of the CMP were affected by the addition of Triton X-100. Conclusions: Detergent-based inactivation of plasma specimens may be a viable approach to mitigating the risk that certain blood-borne pathogens pose to laboratory workers in an outbreak setting. However, the effectiveness of this method for inactivation may depend on the specimen type and pathogen in question.
KW - biocontainment
KW - biosafety
KW - laboratory contamination
UR - http://www.scopus.com/inward/record.url?scp=85116957950&partnerID=8YFLogxK
U2 - 10.1093/jalm/jfab006
DO - 10.1093/jalm/jfab006
M3 - Article
C2 - 33993264
AN - SCOPUS:85116957950
SN - 2576-9456
VL - 6
SP - 1123
EP - 1132
JO - The journal of applied laboratory medicine
JF - The journal of applied laboratory medicine
IS - 5
ER -